Scarica l'app Stockscreener
10.80
5.99%
0.61
Pre-mercato:
10.90
0.10
+0.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.19
Aprire:
$10.4
Volume 24 ore:
11.86M
Relative Volume:
0.72
Capitalizzazione di mercato:
$4.89B
Reddito:
$285.55M
Utile/perdita netta:
$-353.86M
Rapporto P/E:
-11.37
EPS:
-0.9501
Flusso di cassa netto:
$-305.02M
1 W Prestazione:
+7.78%
1M Prestazione:
+34.00%
6M Prestazione:
+198.34%
1 anno Prestazione:
+409.43%
Intervallo 1D:
$10.15
$10.83
Intervallo di 1 settimana:
$9.83
$10.85
Portata 52W:
$1.76
$10.98
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
10.80 | 4.89B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Aggiornamento | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Why Iovance Biotherapeutics Stock Was on Fire Today - Yahoo Finance
IOVA Reinstated by Goldman Sachs -- Buy Rating with Price Target of $15.00 - gurufocus.com
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics (IOVA) w - gurufocus.com
Iovance Biotherapeutics, Inc. (IOVA) Options ChainYahoo Finance - Yahoo! Finance Canada
Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance Biotherapeutics, Inc. (IOVA) stock price, news, quote and history - Yahoo Finance UK
Iovance Biotherapeutics stock extends rally after strong earnings and cancer therapy momentum - AD HOC NEWS
IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Iovance Biotherapeutics Stock: 6 Straight Green Days, Up 26% - Trefis
Why Did Iovance Biotherapeutics (IOVA) Move Today? - Yahoo Finance
Iovance Biotherapeutics (IOVA) Is Up 19.2% After Record Q2 Amtagvi Revenue And TIL Pipeline Expansion - Yahoo Finance
Iovance Biotherapeutics (IOVA) Stock Fair Value Edges Higher On Amtagvi Margin Progress - Yahoo Finance
Is Iovance Biotherapeutics (IOVA) Trading At A Premium To Sales? - Yahoo Finance
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics (IOVA) Stock Forum and Discussion - Moomoo
Iovance Biotherapeutics (IOVA) Puts Buyer Nets 64% Gain as Marke - gurufocus.com
Iovance Biotherapeutics (IOVA) Stock Analysis: Unpacking the 65.7% Revenue Growth Potential - DirectorsTalk Interviews
$Iovance Biotherapeutics (IOVA.US)$ - Moomoo
$Iovance Biotherapeutics (IOVA.US)$ Talking a profit here and waiting for it to come down closer to 9 ema - Moomoo
IOVA Maintained by Barclays -- Price Target Raised to $15.00 - GuruFocus
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $15 - Moomoo
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Iovance Biotherapeutics stock hits 52-week high at 9.36 USD By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics stock hits 52-week high at 9.36 USD - Investing.com
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - Stocktwits
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Iovance Biotherapeutics' Chief Regulatory Officer Reports RSU Vesting and Tax Withholding Transactions - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com Australia
Iovance Biotherapeutics (IOVA) Slips 3.10% to $8.43 as Support at $8.01 Comes Into FocusAlgorithmic Stock Picks - careplusvn.com
Iovance Biotherapeutics stock trends on sector momentum, Q2 beat - scanx.trade
Why Is IOVA Stock Falling Today? - Stocktwits
NFLX: Netflix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
How Iovance Biotherapeutics Inc. (IOVA) Affects Rotational Strategy Timing - Stock Traders Daily
Iovance Biotherapeutics Stock Price Forecast. Should You Buy IOVA? - StockInvest.us
Iovance Biotherapeutics, Inc. (IOVA) Latest Press Releases & Corporate News - Yahoo Finance
Iovance Biotherapeutics, Inc. (IOVA) Latest Stock News & Headlines - Yahoo Finance
Iovance Biotherapeutics to Present at Upcoming Conferences - The Manila Times
Iovance Biotherapeutics (IOVA) Stands Out with Strong Quant Rati - GuruFocus
Iovance Biotherapeutics (IOVA) Wins FDA Trial Clearance, Is The Stock Still 54% Undervalued? - sahmcapital.com
Iovance Biotherapeutics Inc. (IOVA) Peer Comparison – Compare with Others - Value Research
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Eastern Progress
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates - Eastern Progress
Biotech company Iovance grants 20 new employees options with an $8.99 exercise price - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8%Here's Why - MarketBeat
IOVA Stock Pulls Back As Biotech Momentum Cools - StocksToTrade
UBS Lifts Iovance Biotherapeutics Price Target as Cancer Drug Sales Top Expectations - TIKR.com
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? - Benzinga
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
1.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):